secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2023-05-16T23:59:59+00:00
Accession:  0001193125-23-146091
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AlloVir stockholder vote approves doubling authorized common shares to 300M
---------------------------------------------------------------------------

- Charter amendment filed May 15 increases authorized common from 150M to 300M shares.
- Proposal 3 approved: 86,571,410 for, 544,049 against, 1,225 abstain.
- Class III directors elected: Bornstein, Brainard, Hallal, Tomasello; vote totals provided.
- Ratification of Deloitte & Touche as auditor for FY2023 approved: 86,411,460 for.
- Record date March 15, 2023; 93,511,558 shares outstanding and entitled to vote.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312523146091/0001193125-23-146091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312523146091/d468524d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-146091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer